Hematology

Sickle cell disease; hemolytic anemia; immune-mediated cytopenia; PNH
Visit the Ware Lab.

Biography

Russell Ware, MD, PhD, has been involved with a wide variety of clinical and translational hematology research projects for over 25 years, but his primary interests have focused on sickle cell disease. Dr. Ware has substantial personal experience with directing patient-oriented research, and he currently runs an NIH-funded laboratory effort that investigates genetic modifiers of sickle cell disease. The main focus of his lab research is to understand the phenotypic variability that occurs with hydroxyurea treatment, through the study of hydroxyurea pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics. Dr. Ware is also the national principal investigator for several NIH-funded multicenter sickle cell clinical trials, including the recently completed Stroke With Transfusions Changing to Hydroxyurea (SWiTCH), and the current TCD With Transfusions Changing to Hydroxyurea (TWiTCH) and Sparing Conversion to Abnormal TCD Elevations (SCATE) studies that include non-US clinical sites. Most recently, Dr. Ware has moved his research efforts into the international arena, starting SCD pilot screening programs in Angola, and now conducting clinical trials to determine the safety and efficacy of hydroxyurea in developing countries.

MD: Duke University School of Medicine, Durham, NC, 1979-83.

Residency: Baylor College of Medicine, Houston, TX, 1983-86.

Fellowship: Duke Medical Center, Durham, NC, 1986-89.

PhD: Duke University School of Medicine, Durham, NC, 1987-91.

Certification: Pediatric Hematology/Oncology.

Ndeezi G, Kiyaga C, Hernandez AG, Munube D, Howard TA, Ssewanyana I, Nsungwa J, Kiguli S, Ndugwa CM, Ware RE, Aceng JR. Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): a cross-sectional study. Lancet Glob Health. 2016 Mar;4(3):e195-e200.

Aygun B, Mortier NA, Kesler K, Schultz WH, Alvarez O, Rogers Z, Kwiatkowski J, Miller S, Sylvestre P, Cohen A, Ware RE. Therapeutic phlebotomy is safe in children with sickle cell anemia and can be effective treatment for transfusional iron overload. Br J Haematol. 2015;169(2):262-266.

Ware RE, Davis BR, Schultz WH, Brown, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel, Adams RJ. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2015 Feb;387(10019):661-670.

Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014 Sep 10;312(10):1033-48.

Ware RE. Is sickle cell anemia a neglected tropical disease? PLoS Negl Trop Dis. 2013 May 30;7(5):e2120.

Ware RE and Helms RW for the SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119(17):3925-3932.

Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer M, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985-4991.

Wang WC, Ware RE, Miller ST, Iyer RV, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicenter, randomized, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.

Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145:346-352.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematological efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039-2045.

Faculty

Ralph A. Gruppo, MD Director, Comprehensive Hemophilia and Thrombosis Center

research involves numerous clinical trials of promising therapies for hemophilia, von Willebrand Disease, and hemolytic uremic syndrome. His research also includes the study of thrombosis in children, including the use of site-directed thrombolytic therapy in the prevention of long-term complications of thrombosis.

513-636-8617 ralph.gruppo@cchmc.org

High Res

Ralph A. Gruppo, MD

Director, Comprehensive Hemophilia and Thrombosis Center

Director, Research Coagulation Laboratory

Director, Special Hemostasis & Thrombosis Laboratory

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-8617

Fax 513-636-5599

Email ralph.gruppo@cchmc.org

Show All

Clinical Interests

Coagulation; hemophilia; thrombosis

MD: Johns Hopkins Medical School, Baltimore, MD, 1967.

Residency: Children's Hospital Medical Center, Cincinnati, Ohio; Johns Hopkins School of Medicine, Baltimore, MD, 1970.

Fellowship: Children's Hospital Medical Center, Cincinnati, OH, 1974.

Certification: Pediatrics, 1975; Pediatric Hematology/Oncology, 1976.

Gruppo RA. Treatment of hemophilia in developing countries: a journey of a thousand miles. Pediatr Blood Cancer. 2010 Mar;54(3):348-9. No abstract available

Gelfand MJ, Gruppo RA, Nasser MP. Ventilation-perfusion scintigraphy in children and adolescents is associated with a low rate of indeterminate studies. Clin Nucl Med. 2008 Sep;33(9):606-9.

Wu SW, Graham B, Gelfand MJ, Gruppo RE, Dinopolous A, Gilbert DL. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord. 2007 Sep 15;22(12):1813-5.

Balasa VV, Gruppo RA, Glueck CJ, Wang P, Roy DR, Wall EJ, Mehlman CT, Crawford AH. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am. 2004 Dec;86-A(12):2642-7.

Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII -- a robust meta-analytic finding. Haemophilia. 2004 Sep;10(5):449-51.

Morrison JA, Gruppo R, Glueck CJ, Stroop D, Fontaine RN, Wang P, Smith KL. Population-specific alleles: the polymorphism (K121Q) of the human glycoprotein PC-1 gene is strongly associated with race but not with insulin resistance in black and white children. Metabolism. 2004 Apr;53(4):465-8.

Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis -- a meta-analysis. Haemophilia. 2003 May;9(3):251-60. Review.

Balasa VV, Kalinyak KA, Bean JA, Stroop D, Gruppo RA. Hyperhomocysteinemia is associated with low plasma pyridoxine levels in children with sickle cell disease. J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):374-9.

McNamara JL, Lombardi JP, Ferguson R, Manning PB, Gruppo RA. Alternative methods for anticoagulation monitoring in pediatric patients with applicability to a patient with severe hemophilia A and circulating inhibitor. J Extra Corpor Technol. 2001 Dec;33(4):239-42.

Gruppo R, Degrauw A, Fogelson H, Glauser T, Balasa V, Gartside P. Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. J Pediatr. 2000 Nov;137(5):714-8.

Theodosia A. Kalfa, MD, PhD

focuses on the study of intracellular signals in erythropoiesis and mature red blood cells, specifically the signals conducted by Rho GTPases regulating terminal erythroid maturation and enucleation. Her lab also studies the role of Rac GTPases in generation of reactive oxygen species (ROS) within red blood cells from patients and animal models with sickle-cell disease along with the signaling mechanisms and consequences of increased ROS in sickle cells.
Visit the Kalfa Lab.

513-636-0989 theodosia.kalfa@cchmc.org

High Res

Theodosia A. Kalfa, MD, PhD

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-0989

Fax 513-636-3549

Email theodosia.kalfa@cchmc.org

Show All

Research Interests

Signaling in erythrocytes; erythropoiesis; sickle cell disease; reactive oxygen species

Visit the Kalfa Lab.

MD: Aristotle University Medical School, Thessaloniki, Greece, 1990.

PhD: Aristotle University Medical School, Thessaloniki, Greece, 1997.

Residency: University Of North Carolina, Chapel Hill, NC, 1999.

Fellowship: Duke University Medical Center, Durham, NC, 2003.

Certification: Hematology / oncology, American Board of Pediatrics, 2004; Pediatrics, American Board of Pediatrics, 2000; ECFMG Certification, 1995.

Licenses: Full and unrestricted medical license (OH Medical Board), 2003-present; full and unrestricted license of medical practice in Greece, 1990-present.

George A, Pushkaran S, Konstantinidis DG, Koochaki S, Malik P, Mohandas N, Zheng Y, Joiner CH, Kalfa TA. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood. 2013 Mar 14;121(11):2099-107.

Konstantinidis DG, Pushkaran S, Johnson JF, Cancelas JA, Manganaris S, Harris CE, Williams DA, Zheng Y, Kalfa TA. Signaling and cytoskeletal requirements in erythroblast enucleation. Blood. 2012 Jun 21;119(25):6118-27.

Hammill AM, Risinger MA, Joiner CH, Keddache M, Kalfa TA. Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient. Br J Haematol. 2011 Jan 31.

Kalfa TA. Anchoring at an island to relieve stress. Blood. 2011 Jan 20;117(3):748-9.

Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2010 Oct 14.

Konstantinidis DG, George A, Kalfa TA. Rac GTPases in erythroid biology. Transfus Clin Biol. 2010 Sep;17(3):126-30.

Kalfa TA, Pushkaran S, Zhang X, Johnson JF, Pan D, Daria D, Geiger H, Cancelas JA, Williams DA, Zheng Y. Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. Haematologica. 2010 Jan;95(1):27-35.

Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood. 2010 Feb 4;115(5):936-47.

Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.

Daria D, Filippi MD, Knudsen ES, Faccio R, Li Z, Kalfa T, Geiger H. The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood. 2008 Feb 15;111(4):1894-902.

Grants

Rho GTPases in Terminal Erythroid Maturation. Principal Investigator. NIH/NHLBI. Sep 2012-Jun 2016. #1R01HL116352.

Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-investigator. NIH/NHLBI. Aug 2013–May 2018. # U01 HL117709.

Karen A. Kalinyak, MD Director, Outcomes & Quality Improvement

conducts research to understand the clinical course of sickle-cell disease and determine how to prevent or minimize complications. She served as local PI in numerous multi-institutional clinical trials, including Prophylactic Penicillin Study (PROPS II), Stroke with Transfusions Changing to Hydroxyurea (SWiTCH) Trial, Silent Infarct Transfusion Trial (SIT) and two SCD Clinical Research Network studies (PROACTIVE and IMPROVE).

513-636-4266 karen.kalinyak@cchmc.org

High Res

Karen A. Kalinyak, MD

Director, Outcomes & Quality Improvement

Medical Director, Sickle Cell Clinic

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-4266

Fax 513-636-5845

Email karen.kalinyak@cchmc.org

Show All

Clinical Interests

Hematology; bone marrow failure; sickle cell anemia; hemoglobinopathy

MD: Temple University, Philadelphia, PA, 1977.

Residency: Children's Hospital Medical Center, Cincinnati, OH, 1980.

Fellowship: Children's Hospital Medical Center, Cincinnati, OH, 1983.

Certification: Pediatrics, 1984; Pediatric Hematology/Oncology, 1987.

King AA, Rodeghier MJ, Panepinto JA, Strouse JJ, Casella JF, Quinn CT, Dowling MM, Sarnaik SA, Thompson AA, Woods GM, Minniti CP, Redding-Lallinger RC, Kirby-Allen M, Kirkham FJ, McKinstry R, Noetzel MJ, White DA, Kwiatkowski JK, Howard TH, Kalinyak KA, Inusa B, Rhodes MM, Heiny ME, Fuh B, Fixler JM, Gordon MO, DeBaun MR. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol. 2014 Oct;89(10):E188-92.

DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014 Aug 21; 371(8):699-710.

Crosby LE, Barach I, McGrady ME, Kalinyak KA, Eastin AR, Mitchell MJ. Integrating interactive web-based technology to assess adherence and clinical outcomes in pediatric sickle cell disease. Anemia. 2012;2012:492428.

Debaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele G, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Gordon MO, Miller JP, Ichord RN, Casella JF. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure. Blood. 2012 Apr;119(16):3684-90.

McCarville MB, Rogers ZR, Sarnaik S, Scott P, Aygun B, Hilliard L, Lee MT, Kalinyak K, Owen W, Garro J, Schultz W, Yovetich N, Ware RE, SWiTCH Investigators. Effects of Chronic Transfusions on Abdominal Sonographic Abnormalities in Children with Sickle Cell Anemia. J Pediatr. 2012 Feb;160(2):281-285.

Kwiatkowski JL, Yim E, Miller S, Adams RJ, STOP 2 Study Investigators. Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease. Pediatr Blood Cancer. 2011 May;56(5):777-82.

George A, Benton J, Pratt J, Kim MO, Kalinyak KA, Kalfa TA, Joiner CH. The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. Pediatr Blood Cancer. 2011 Feb.

Wang W, Brugnara C, Snyder C, Wynn L, Rogers Z, Kalinyak K, Brown C, Qureshi A, Bigelow C, Neumayr L, Smith-Whitley K, Chui DH, Delahunty M, Woolson R, Steinberg M, Telen M, Kesler K. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. Br J Haematol. 2011 Jan;1365-2141.

Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W, Comprehensive Sickle Cell Centers Clinical Trial Consortium. Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Center Clinical Trial Consortium (CTC). Pediatr Blood Cancer. 2010 Sep;55(3):485-94.

Patrick T. McGann, MD, MS

focuses his research efforts on improving the diagnosis, care, and outcomes for children with sickle cell anemia across the world, particularly in sub-Saharan Africa. Current projects include the investigation of hydroxyurea in Africa (REACH), the development and testing of inexpensive point-of-care diagnostics in hematology, and analysis of serotype distribution of invasive pneumococcal disease in Angola.

513-803-4991 patrick.mcgann@cchmc.org

High Res

Patrick T. McGann, MD, MS

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-803-4991

Email patrick.mcgann@cchmc.org

Show All

Biography

Dr. McGann was a leader in the development of a newborn screening and treatment program in the Republic of Angola. Toward this end, he worked and lived in Angola for much of two and a half years. This work helped to develop many relationships and is the foundation for much of his continued research and public health efforts in Angola. His research efforts during this time were supplemented by formal training in clinical research through the American Society of Hematology's Clinical Research Training Institute and through the master's program in clinical research at Baylor College of Medicine.

He is also actively involved in global hematology and global child health through such organizations as the Global Sickle Cell Disease Network, the Central African Sickle Cell Network (REDAC), the American Society of Hematology, and the AAP's Section on International Child Health (SOICH).

Upon arrival to Cincinnati Children's, Dr. McGann was the recipient of the Procter Scholar Award, which will help to support his international research efforts.

MD: Tufts University School of Medicine, Boston, MA, 2006.

Residency: Pediatrics, Massachusetts General Hospital, Boston, MA, 2009.

Fellowship: Pediatric Hematology-Oncology, St. Jude Children's Research Hospital, 2009-2011; Baylor College of Medicine, 2011-2012.

MS: Clinical Research, Baylor College of Medicine, 2013.

Board Certification: Pediatrics, 2009; Pediatric Hematology-Oncology, 2013.

McGann PT, Bernardino L. Anemia falciforme: um grande problema de saúde pública em Angola. Jornal Angolano de Medicina. 2013; 1(3).

McGann PT, Ferris MG, Ramamurthy, U, Santos, B, de Oliveira V, Bernardino L, Ware RE. A pilot newborn screening and treatment for sickle cell anemia in the Republic of Angola. Am J Hematol. 2013; 88(12):984-989.

Despotovic JM, McGann PT, Smeltzer MP, Aygun B, Ware RE. RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia. Pediatr Blood Cancer. 2013; 60(9):E106-108.

McGann PT, Flanagan JM, Howard TA, Dertinger SD, He J, Kulharya A, Thompson BW, Ware RE. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY-HUG phase III clinical trial. Pediatr Blood Cancer. 2012; 59(2) 254-257.

McGann PT, Despotovic JM, Howard TA, Ware RE. A novel laboratory technique demonstrating the influences of RHD zygosity and the RhCcEe phenotype on erythrocyte D antigen expression. Am J Hematol. 2012; 87(3): 266-271.

McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Curr Opin Hematol. 2011 May;18(3):158-65.

McGann PT, Howard TA, Flanagan JM, Lahti JM, Ware RE. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol. 2011; 154(1):134-40.

McGann PT, McDade J, Mortier NA, Combs MR, Ware RE. IgA-mediated autoimmune hemolytic anemia in an infant. Pediatr Blood Cancer. 2011; 56(5):837-9.

McDade J, McGann PT. 50 Years Ago in The Journal of Pediatrics: Autohemolytic Anemia in Young Infants. J Pediatr. 2011; 159(1):69.

McGann PT, Ware RE. 50 years ago in the journal of pediatrics overwhelming infection in children following splenectomy. J Pediatr. 2010; 157(2):202.

Grants

A Phase I/II Study of Hydroxyurea for Children with Sickle Cell Anemia in Angola. Principal Investigator. Procter Scholar Award, Cincinnanti Children's Hospital Medical Center TAPS Program. Jan 2014-Dec 2016.

Sickle Cell Education and Screening for Angolan Adolescents. Co-Director/Mentor. AAP International Community Access to Child Health (ICATCH). Jan 2014-Dec 2016.

Eric Mullins, MD Research Director, Hemophilia Treatment Center

has a research interest in the interplay between the hemostatic system and the immune system in the setting of inflammatory diseases and infection.

513-636-4266 eric.mullins@cchmc.org

High Res

Eric Mullins, MD

Research Director, Hemophilia Treatment Center

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-4266

Fax 513-636-3549

Email eric.mullins@cchmc.org

Show All

Clinical & Research Interests

Clinical

Care of children and adolescents with bleeding and thrombotic disorders; hemophilia; von Willebrand’s disease; Young Women’s Bleeding Disorder Clinic; disordered menstrual bleeding; Hemophilia Treatment Center

Research

Interaction of coagulation factors with immunity and inflammation; inflammatory diseases; multiple sclerosis; sickle cell disease; mouse models of these diseases; coagulation factor knockouts; how hemostatic factors modify the inflammatory response

MD: University of Missouri, Columbia, MO.

Residency: Vanderbilt University Medical Center, Nashville, TN, 2001-2004.

Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2004-2007; Pediatric Hemostasis Fellowship, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008; Chief Fellow, Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008.

Board Certifications: Pediatrics, 2004-Present; Pediatric Hematology/Oncology, 2009-Present.

Raghu H, Cruz C, Rewerts CL, Frederick MD, Thornton S, Mullins ES, Schoenecker JG, Degen JL, Flick MJ. Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion. Blood. 2014 Oct 21.

Huang Y, Shaw MA, Mullins ES, Kirley TL, Ayres N. Synthesis and anticoagulant activity of polyureas containing sulfated carbohydrates. Biomacromolecules. 2014 Oct 20.

Turpin B, Miller W, Rosenfeldt L, Kombrinck K, Flick MJ, Steinbrecher KA, Harmel-Laws E, Mullins ES, Shaw M, Witte DP, Revenko A, Monia B, Palumbo JS. Thrombin drives tumorigenesis in colitis-associated colon cancer. Cancer Res. 2014 Jun 1;74(11):3020-30.

Davalos D, Baeten KM, Whitney MA, Mullins ES, Friedman B, Olson ES, Ryu JK, Smirnoff DS, Petersen MA, Bedard C, Degen JL, Tsien RY, Akassoglou K. Early detection of thrombin activity in neuroinflammatory disease. Ann Neurol. 2014 Feb;75(2):303-8.

Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KT, Mullins ES, Flick MJ, Queiroz KCS, Speck CA, Conway EM, Monia BP, Weiler H, Degen JL, Palumbo J. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood. 2011;118:2889-95.

Flick MJ, Chauhan AK, Frederick M, Talmage KE, Kombrinck KW, Miller W, Mullins ES, Palumbo JS, Zheng X, Esmon NL, Esmon CT, Thornton S, Becker A, Pelc LA, Di Cera E, Wagner DD, Degen JL. The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood. 2011;117:6326-37.

Mullins ES, Kombrinck KW, Talmage KE, Shaw MA, Witte DP, Ullman JM, Degen SJ, Sun W, Flick MJ, Degen JL. Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood. 2009;113:676-704.

Joseph S. Palumbo, MD Director, Comprehensive Thrombophilia Center

focuses on interactions between the hemostatic system and innate immunity effecting tumor progression and Langerhans' cell histiocytosis.

513-636-4266 joe.palumbo@cchmc.org

High Res

Joseph S. Palumbo, MD

Director, Comprehensive Thrombophilia Center

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-4266

Fax 513-636-3549

Email joe.palumbo@cchmc.org

Show All

Clinical Interests

Interactions between the hemostatic system and innate immunity effecting tumor progression; Langerhans' cell histiocytosis

MD: Pennsylvania State University College of Medicine, Hershey, PA, 1993.

Residency: Childrens Hospital Medical Center, Cincinnati, OH, 1997.

Fellowship: Childrens Hospital Medical Center, Cincinnati, OH, 2000.

Subspecialty: Pediatric Hematology / Oncology.

Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KE, Mullins ES, Flick MJ, Queiroz KC, Shi K, Spek CA, Conway EM, Monia BP, Weiler H, Degen JL, Palumbo JS. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood. 2011 Jul 25.

Akunuru S, Palumbo J, Zhai QJ, Zheng Y. Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. PLoS One. 2011 Feb 9;6(2):e16951.

Palumbo JS, Degen JL. Mechanisms coupling the hemostatic system to colitis-associated cancer. Thromb Res. 2010 Apr;125 Suppl 2:S39-43. Review.

Steinbrecher KA, Horowitz NA, Blevins EA, Barney KA, Shaw MA, Harmel-Laws E, Finkelman FD, Flick MJ, Pinkerton MD, Talmage KE, Kombrinck KW, Witte DP, Palumbo JS. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res. 2010 Apr 1;70(7):2634-43.

Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost. 2008 Mar;34(2):154-60. Review.

Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, Kombrinck KW, Talmage KE, Souri M, Ichinose A, Degen JL. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost. 2008 May;6(5):812-9.

Palumbo JS, Degen JL. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res. 2007;120 Suppl 2:S22-8.

Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007 Nov;117(11):3224-35.

Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007 Jul 1;110(1):133-41.

Charles T. Quinn, MD, MS Director, Erythrocyte Diagnostic Laboratory

focuses on characterization and treatment of cardiomyopathy and nephropathy in sickle cell disease; measurement of red blood cell turnover in sickle cell disease; pathophysiology, treatment and prevention of brain injury (structural and cognitive) in sickle cell disease; MRI methods of body iron quantitation; and new agents for immune thrombocytopenia (ITP).

513-636-4266 charles.quinn@cchmc.org

High Res

Charles T. Quinn, MD, MS

Director, Erythrocyte Diagnostic Laboratory

Medical Director, Pediatric Sickle Cell Program

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-4266

Fax 513-636-5845

Email charles.quinn@cchmc.org

Show All

Clinical & Research Interests

Clinical

Sickle cell disease; thalassemia; hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; immune thrombocytopenia (ITP); neutropenia; stroke

Research

Epidemiology, pathophysiology, treatment and prevention of brain injury (structural and cognitive) in sickle cell disease; measurement of red blood cell turnover in sickle cell disease; identification and treatment of cardiomyopathy and nephropathy in sickle cell disease; treatment and prevention of pain (VOC) in sickle cell disease; MRI methods of iron quantitation; new agents for immune thrombocytopenia (ITP)

Biography

Dr. Quinn’s main interests and expertise are in patient-oriented and translational research in sickle cell disease and thalassemia. His formal clinical and translational research training has included: (1) the NIH-K30 Curriculum in Patient-Oriented Research; (2) the Clinical Research Training Institute of the American Society of Hematology; (3) the NIH-K12/KL2 Clinical Scholars Program; and (4) a master’s degree in clinical sciences. Dr. Quinn is a member of the Editorial Board for Pediatric Blood and Cancer. Locally, he is the medical director of the Pediatric Sickle Cell Disease Program; medical director of the Erythrocyte Diagnostic Laboratory, and medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.

MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.

MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.

Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.

Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.

Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.

Niss O, Quinn CT, Lane A, Daily J, Khoury PR, Bakeer N, Kimball TR, Towbin JA, Malik P, Taylor MD. Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease. JACC Cardiovasc Imaging. 2016 Mar;9(3):243-52.

Quinn CT, St Pierre TG. MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls. Pediatr Blood Cancer. 2016 May;63(5):773-80.

Serai SD, Fleck RJ, Quinn CT, Zhang B, Podberesky DJ. Retrospective comparison of gradient recalled echo R2* and spin-echo R2 magnetic resonance analysis methods for estimating liver iron content in children and adolescents. Pediatr Radiol. 2015 Oct;45(11):1629-34.

King AA, Rodeghier MJ, Panepinto JA, Strouse JJ, Casella JF, Quinn CT, Dowling MM, Sarnaik SA, Thompson AA, Woods GM, Minniti CP, Redding-Lallinger RC, Kirby-Allen M, Kirkham FJ, McKinstry R, Noetzel MJ, White DA, Kwiatkowski JK, Howard TH, Kalinyak KA, Inusa B, Rhodes MM, Heiny ME, Fuh B, Fixler JM, Gordon MO, DeBaun MR. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol. 2014 Jul 15.

Vetter CL, Buchanan GR, Quinn CT. Burden of diagnostic radiation exposure in children with sickle cell disease. Pediatr Blood Cancer. 2014 Jul;61(7):1322-4.

Dowling MM, Noetzel MJ, Rodeghier MJ, Quinn CT, Hirtz DG, Ichord RN, Kwiatkowski JL, Roach ES, Kirkham FJ, Casella JF, DeBaun MR. Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction. J Pediatr. 2014 May;164(5):1175-1180.e1.

Chandrakasan S, Bakeer N, Mo JQ, Cost C, Quinn CT. Iron-refractory microcytic anemia as the presenting feature of unicentric Castleman disease in children. J Pediatr. 2014 Apr;164(4):928-30.

King AA, Strouse JJ, Rodeghier MJ, Compas BE, Casella JF, McKinstry RC, Noetzel MJ, Quinn CT, Ichord R, Dowling MM, Miller JP, Debaun MR. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol. 2014 Feb;89(2):162-7.

Quinn CT. Sickle cell disease in childhood: from newborn screening through transition to adult medical care. Pediatr Clin North Am. 2013 Dec;60(6):1363-81.

Grants

Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-PI. National Institutes of Health. Aug 2013–May 2018. U01 HL117709.

Susan R. Rose, MD Member, Division of Endocrinology

investigates hypothalamic pituitary function and disorders of growth, puberty or thyroid hormone. She has special interest in the effects of neural injury on hypothalamic-pituitary function, such as after traumatic brain injury, cranial radiation, anoxia, iron overload.

513-636-4744 susan.rose@cchmc.org

High Res

Susan R. Rose, MD

Member, Division of Endocrinology

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-4744

Email susan.rose@cchmc.org

Show All

Clinical & Research Interests

Clinical

Neuro-endocrinology; hypothalamic-pituitary injury; growth disorders; puberty disorders; thyroid disorders; late effects of cancer

Research

Hypothalamic-pituitary function

Biography

Susan Rose is professor for the Division of Endocrinology at Cincinnati Children’s Hospital Medical Center within the University of Cincinnati. She has published over 100 review articles or chapters, and about 100 peer-reviewed articles. These include updating guidelines for care of congenital hypothyroidism and writing the chapter on thyroid for Fanaroff's and Avery's textbooks of neonatology. She’s served on the state newborn screening (NBS) committee in Tennessee. She is involved in long term follow up of newborn screening for CAH and congenital hypothyroidism with Region 4 and with the Federal Workgroup on NBS Standards.

She has clinical expertise and research interests in hypothalamic pituitary function, thyroid hormone disorders, and in disorders of growth or puberty. She has a special interest in the effects of central nervous system injury on hypothalamic-pituitary function. In addition, she has expertise and experience in evaluating the endocrine conditions associated with congenital bone marrow failure syndromes such as Fanconi anemia, Blackfan Diamond anemia, and Shwachman-Diamond syndrome. In addition, she is evaluating the endocrine consequences of hypothalamic-pituitary injury, including traumatic brain injury and injury from treatments for cancer, as well as comparing the relative efficacy of several treatments for precocious puberty. In this study, she will be developing growth curves specific to Fanconi anemia, recognizing that healthy children with FA may not grow along the typical growth pattern of other healthy children.

MD: Case Western Reserve School of Medicine, 1980.

MEd: School Psychology, University of Dayton, 1972.

Residency: The Cleveland Clinic, 1983.

Fellowship: National Institutes of Health, 1986.

Certification: Pediatrics, 1985; Pediatric Endocrinology, 1986.